LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Atidarymo kaina

28.77 1.52

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.86

Max

29.06

Pagrindiniai rodikliai
By Trading Economics
Pajamos	43M 13M
Pardavimai	29M 107M
Pelnas, tenkantis vienai akcijai	0.25
Pelno marža	12.139
Darbuotojai	524
EBITDA	16M 8.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+128.37% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	17M 1.5B
Ankstesnė atidarymo kaina	27.25
Ankstesnė uždarymo kaina	28.77

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-28 22:47; UTC

Uždarbis

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

2026-05-28 20:45; UTC

Uždarbis

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

2026-05-28 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

2026-05-28 23:39; UTC

Rinkos pokalbiai

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

2026-05-28 23:31; UTC

Rinkos pokalbiai

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

2026-05-28 23:17; UTC

Rinkos pokalbiai

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

2026-05-28 23:02; UTC

Rinkos pokalbiai

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

2026-05-28 22:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-28 22:41; UTC

Rinkos pokalbiai

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

2026-05-28 22:37; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

M&A-Related Insurance Payments In North America Rise -- Market Talk

2026-05-28 22:04; UTC

Įsigijimai, susijungimai, perėmimai

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

2026-05-28 22:04; UTC

Įsigijimai, susijungimai, perėmimai

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

2026-05-28 21:12; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026-05-28 21:00; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

2026-05-28 20:57; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026-05-28 20:55; UTC

Uždarbis

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

2026-05-28 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-28 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-28 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-28 20:48; UTC

Karštos akcijos

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

2026-05-28 20:34; UTC

Uždarbis

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

2026-05-28 20:31; UTC

Uždarbis

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

2026-05-28 20:28; UTC

Uždarbis

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

2026-05-28 20:26; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026-05-28 20:20; UTC

Uždarbis

Costco 3Q Membership Fees $1.37B

2026-05-28 20:20; UTC

Uždarbis

Costco 3Q Net Sales $69.15B

2026-05-28 20:19; UTC

Uždarbis

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

2026-05-28 20:19; UTC

Uždarbis

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

2026-05-28 20:17; UTC

Uždarbis

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

2026-05-28 20:17; UTC

Uždarbis

Costco 3Q Same-Store Sales Up 9.8% >COST

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

128.37% į viršų

12 mėnesių prognozė

Vidutinis 65.13 USD 128.37%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.